Literature DB >> 16096877

The history of DES, lessons to be learned.

Marieke Veurink1, Marlies Koster, Lolkje T W de Jong-van den Berg.   

Abstract

Since the 1940s, diaethylstilbestrol (DES) has been used by millions of pregnant women to prevent miscarriages and many other disorders in pregnancy. In 1971, it became clear that this apparently innocent treatment proved to be a time bomb for the infants exposed to DES during the first trimester of pregnancy. DES is now associated with an increased risk of breast cancer, clear cell adenocarcinoma (CCAC) of the vagina and cervix, and reproductive anomalies. This article summarises the potential long-term health implications of DES on the mother, DES daughters and DES sons, and the possible side effects on the third generation. Health care professionals have to know the history of DES to prevent future disasters with drugs prescribed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096877     DOI: 10.1007/s11096-005-3663-z

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  39 in total

1.  In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing müllerian system.

Authors:  K Block; A Kardana; P Igarashi; H S Taylor
Journal:  FASEB J       Date:  2000-06       Impact factor: 5.191

2.  Age at menarche among diethylstilbestrol granddaughters.

Authors:  A J Wilcox; D M Umbach; P P Hornsby; A L Herbst
Journal:  Am J Obstet Gynecol       Date:  1995-09       Impact factor: 8.661

3.  [Teratogenic effect of diethylstilbestrol during pregnancy; the extent of the DES problem in the Netherlands].

Authors:  J G Stolk; G P Vooijs; E J Aartsen; A P Heintz
Journal:  Ned Tijdschr Geneeskd       Date:  1982-07-24

4.  Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring.

Authors:  R H Kaufman; E Adam; E E Hatch; K Noller; A L Herbst; J R Palmer; R N Hoover
Journal:  Obstet Gynecol       Date:  2000-10       Impact factor: 7.661

5.  The fate of diethylstilbestrol in the pregnant mouse.

Authors:  H C Shah; J A McLachlan
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

6.  Randomised trial of high doses of stilboestrol and ethisterone in pregnancy: long-term follow-up of mothers.

Authors:  V Beral; L Colwell
Journal:  Br Med J       Date:  1980-10-25

7.  Cancer risk among women exposed to exogenous estrogens during pregnancy.

Authors:  O C Hadjimichael; J W Meigs; F W Falcier; W D Thompson; J T Flannery
Journal:  J Natl Cancer Inst       Date:  1984-10       Impact factor: 13.506

8.  Effect of prenatal exposure to diethylstilbestrol on Müllerian duct development in fetal male mice.

Authors:  J A Visser; A McLuskey; M Verhoef-Post; P Kramer; J A Grootegoed; A P Themmen
Journal:  Endocrinology       Date:  1998-10       Impact factor: 4.736

9.  Hormonal risk factors in testicular cancer. A case-control study.

Authors:  A R Moss; D Osmond; P Bacchetti; F M Torti; V Gurgin
Journal:  Am J Epidemiol       Date:  1986-07       Impact factor: 4.897

10.  Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy.

Authors:  L Titus-Ernstoff; E E Hatch; R N Hoover; J Palmer; E R Greenberg; W Ricker; R Kaufman; K Noller; A L Herbst; T Colton; P Hartge
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

View more
  27 in total

1.  Neonatal diethylstilbestrol exposure disrupts female reproductive tract structure/function via both direct and indirect mechanisms in the hamster.

Authors:  Imala D Alwis; Dulce M Maroni; Isabel R Hendry; Shyamal K Roy; Jeffrey V May; Wendell W Leavitt; William J Hendry
Journal:  Reprod Toxicol       Date:  2011-09-24       Impact factor: 3.143

2.  Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society.

Authors:  R Thomas Zoeller; T R Brown; L L Doan; A C Gore; N E Skakkebaek; A M Soto; T J Woodruff; F S Vom Saal
Journal:  Endocrinology       Date:  2012-06-25       Impact factor: 4.736

3.  Effect of estrogen-active compounds on the expression of RACK1 and immunological implications.

Authors:  Erica Buoso; Mirco Masi; Valentina Galbiati; Ambra Maddalon; Martina Iulini; Maša Kenda; Marija Sollner Dolenc; Marina Marinovich; Marco Racchi; Emanuela Corsini
Journal:  Arch Toxicol       Date:  2020-04-23       Impact factor: 5.153

Review 4.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases.

Authors:  Shuk-mei Ho; Wan-yee Tang
Journal:  Reprod Toxicol       Date:  2007-01-19       Impact factor: 3.143

Review 5.  Epigenetic reprogramming and imprinting in origins of disease.

Authors:  Wan-yee Tang; Shuk-mei Ho
Journal:  Rev Endocr Metab Disord       Date:  2007-06       Impact factor: 6.514

6.  Hormone-activated estrogen receptors in annelid invertebrates: implications for evolution and endocrine disruption.

Authors:  June Keay; Joseph W Thornton
Journal:  Endocrinology       Date:  2008-11-26       Impact factor: 4.736

7.  Perinatal exposure to bisphenol-a and the development of metabolic syndrome in CD-1 mice.

Authors:  Karen K Ryan; April M Haller; Joyce E Sorrell; Stephen C Woods; Ronald J Jandacek; Randy J Seeley
Journal:  Endocrinology       Date:  2010-03-29       Impact factor: 4.736

Review 8.  Transgenerational genetic effects on phenotypic variation and disease risk.

Authors:  Joseph H Nadeau
Journal:  Hum Mol Genet       Date:  2009-10-15       Impact factor: 6.150

Review 9.  Reproductive drugs and environmental contamination: quantum, impact assessment and control strategies.

Authors:  Harpreet Kaur; Madhu Bala; Gulshan Bansal
Journal:  Environ Sci Pollut Res Int       Date:  2018-07-23       Impact factor: 4.223

Review 10.  Heightened susceptibility: A review of how pregnancy and chemical exposures influence maternal health.

Authors:  Julia Varshavsky; Anna Smith; Aolin Wang; Elizabeth Hom; Monika Izano; Hongtai Huang; Amy Padula; Tracey J Woodruff
Journal:  Reprod Toxicol       Date:  2019-05-02       Impact factor: 3.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.